Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Target-Preferential Release of Doxorubicin in CXCR4-Expresing Lymphoma Cells

  • De La Torre, Cristina
  • Casanova, Isolda
  • Acosta, Gerardo
  • Coll Merino, Mª Carmen
  • Moreno, María José
  • Albericio, Fernando
  • Mangues, Ramón
  • Royo, Miriam
  • Aznar, Elena|||0000-0003-0361-3876
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] B-cell non-Hodgkin s lymphoma (B-NHL) is the most frequent malignant lymphoid neoplasm, which has a high degree of relapse and chemoresist-ance. Thus, strategies to improve currently used therapies are needed. In this context, a new CXCR4-targeted delivery system is described using mesoporous silica nanoparticles (MSNs) that are loaded with doxorubicin and capped with a derivative of the T22 peptide ( P ). This design makes full use of the great affi nity of the T22 peptide to CXCR4 receptor, which is overexpressed in lymphoma cells. The peptide is able to guide the gated nanoparticle to B-NHL cells to facilitate MSNs uptake via the CXCR4 receptor. The endocyted P -capped MSNs are also opened by endosomal proteolytic enzymes to allow intracellular doxorubicin delivery., Financial support from the Spanish Government (MAT2012-38429-C04 and PIB2010BZ-00563), Generalitat Valenciana (PROMETEOII/2014/047), Generalitat de Catalunya (2009-SGR-1437), Instituto de Salud Carlos III (FI10/00758 and FIS PII2/01861), MaratoTV3 416/C/2013-2030, CIBER-BBN (Nanomets), and Institut de Recerca Josep Carreras Sant Pau is gratefully acknowledged. C.T. is grateful to the Spanish MEC for her grant. The authors also acknowledge Cristina Suarez for her technical support and the use of the CIBER-BBN Nanotoxicology and Synthesis of Peptides platforms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In vivo architectonic stability of fully de novo designed protein-only nanoparticles

  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Tatkiewicz, Witold
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Conchillo-Solé, Oscar|||0000-0003-4266-246X
  • Álamo, Patricia|||0000-0003-0510-5701
  • Xu, Zhikun
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Cedano, Juan|||0000-0003-1380-8036
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Ratera Bastardas, Imma|||0000-0002-1464-9789
  • Veciana i Miró, Jaume|||0000-0003-1023-9923
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
The fully de novo design of protein building blocks for self-assembling as functional nanoparticles is a challenging task in emerging nanomedicines, which urgently demand novel, versatile, and biologically safe vehicles for imaging, drug delivery, and gene therapy. While the use of viruses and virus-like particles is limited by severe constraints, the generation of protein-only nanocarriers is progressively reachable by the engineering of protein-protein interactions, resulting in self-assembling functional building blocks. In particular, end-terminal cationic peptides drive the organization of structurally diverse protein species as regular nanosized oligomers, offering promise in the rational engineering of protein self-assembling. However, the in vivo stability of these constructs, being a critical issue for their medical applicability, needs to be assessed. We have explored here if the cross-molecular contacts between protein monomers, generated by end-terminal cationic peptides and oligohistidine tags, are stable enough for the resulting nanoparticles to overcome biological barriers in assembled form. The analyses of renal clearance and biodistribution of several tagged modular proteins reveal long-term architectonic stability, allowing systemic circulation and tissue targeting in form of nanoparticulate material. This observation fully supports the value of the engineered of protein building blocks addressed to the biofabrication of smart, robust, and multifunctional nanoparticles with medical applicability that mimic structure and functional capabilities of viral capsids.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model

  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Di Nicolantonio, Federica
  • Pavón Ribas, Miguel Ángel
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Trias Folch, Manuel
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Bardelli, Alberto
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Mangues, Ramon|||0000-0003-2661-9525
Although all KRas (protein that in humans is encoded by the KRas gene) point mutants are considered to have a similar prognostic capacity, their transformation and tumorigenic capacities vary widely. We compared the metastatic efficiency of KRas G12V (Kirsten rat sarcoma viral oncogene homolog with valine mutation at codon 12) and KRas G13D (Kirsten rat sarcoma viral oncogene homolog with aspartic mutation at codon 13) oncogenes in an orthotopic colorectal cancer (CRC) model. Following subcutaneous preconditioning, recombinant clones of the SW48 CRC cell line [Kras wild-type (Kras WT)] expressing the KRas G12V or KRas G13D allele were microinjected in the mouse cecum. The percentage of animals developing lymph node metastasis was higher in KRas G12V than in KRas G13D mice. Microscopic, macroscopic, and visible lymphatic foci were 1.5- to 3.0-fold larger in KRas G12V than in KRas G13D mice (P < 0.05). In the lung, only microfoci were developed in both groups. KRas G12V primary tumors had lower apoptosis (7.0 ± 1.2 vs. 7.4 ± 1.0 per field, P = 0.02), higher tumor budding at the invasion front (1.2 ± 0.2 vs. 0.6 ± 0.1, P = 0.04), and a higher percentage of C-X-C chemokine receptor type 4 (CXCR4)-overexpressing intravasated tumor emboli (49.8 ± 9.4% vs. 12.8 ± 4.4%, P < 0.001) than KRas G13D tumors. KRas G12V primary tumors showed Akt activation, and β5 integrin, vascular endothelial growth factor A (VEGFA), and Serpine-1 overexpression, whereas KRas G13D tumors showed integrin β1 and angiopoietin 2 (Angpt2) overexpression. The increased cell survival, invasion, intravasation, and specific molecular regulation observed in KRas G12V tumors is consistent with the higher aggressiveness observed in patients with CRC expressing this oncogene.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models

  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Pavón Ribas, Miguel Ángel
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Trias, Manuel
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Céspedes, María Virtudes|||0000-0003-2956-5833
Mouse colorectal cancer (CRC) models generated by orthotopic microinjection of human CRC cell lines reproduce the pattern of lymphatic, haematological and transcoelomic spread but generate low metastatic efficiency. Our aim was to develop a new strategy that could increase the metastatic efficiency of these models. We used subcutaneous implantation of the human CRC cell lines HCT116 or SW48 prior to their orthotopic microinjection in the cecum of nude mice (SC+ORT). This subcutaneous preconditioning significantly enhanced metastatic dissemination. In the HCT116 model it increased the number and size of metastatic foci in lymph nodes, lung, liver and peritoneum, whereas, in the SW48 model, it induced a shift from nonmetastatic to metastatic. In both models the number of apoptotic bodies in the primary tumour in the SC+ORT group was significantly reduced compared with that in the direct orthotopic injection (ORT) group. Moreover, in HCT116 tumours the number of keratin-positive tumour buddings and single epithelial cells increased at the invasion front in SC+ORT mice. In the SW48 tumour model, we observed a trend towards a higher number of tumour buds and single cells in the SC+ORT group but this did not reach statistical significance. At a molecular level, the enhanced metastatic efficiency observed in the HCT116 SC+ORT model was associated with an increase in AKT activation, VEGF-A overexpression and downregulation of β1 integrin in primary tumour tissue, whereas, in SW48 SC+ORT mice, the level of expression of these proteins remained unchanged. In summary, subcutaneous preconditioning increased the metastatic dissemination of both orthotopic CRC models by increasing tumour cell survival and invasion at the tumour invasion front. This approach could be useful to simultaneously study the mechanisms of metastases and to evaluate anti-metastatic drugs against CRC.